Opioid addiction is a serious problem in the United States, with approximately 2.1 million people suffering from an opioid use disorder in 2018.1 Opioid withdrawal symptoms can be debilitating and can include anxiety, nausea, vomiting, diarrhea, muscle aches, and insomnia.2 Until recently, there were limited options for treating opioid withdrawal symptoms, but the approval of Lucemyra (lofexidine hydrochloride) in 2018 has revolutionized the treatment of opioid withdrawal symptoms.
Lucemyra is an oral medication approved by the U.S. Food and Drug Administration (FDA) for the mitigation of opioid withdrawal symptoms.3 It is a selective alpha-2-adrenergic receptor agonist that works by reducing the release of norepinephrine, a neurotransmitter that is involved in the body’s response to stress.4 By blocking the release of norepinephrine, Lucemyra reduces the symptoms of opioid withdrawal.
Lucemyra is typically used in conjunction with other medications and behavioral therapies to treat opioid withdrawal symptoms. It is administered as an oral solution and is typically taken twice a day for up to 14 days.5 The dosage of Lucemyra is based on the patient’s age, weight, and severity of symptoms.6
The most significant benefit of Lucemyra is its ability to reduce the severity of opioid withdrawal symptoms.7 Studies have shown that it can reduce the severity of symptoms such as anxiety, nausea, vomiting, diarrhea, muscle aches, and insomnia.8 It also has fewer side effects than other medications used to treat opioid withdrawal symptoms, such as clonidine.9 In addition to its effectiveness in treating opioid withdrawal symptoms, Lucemyra has also been shown to be effective in helping patients maintain abstinence from opioids.10 Studies have found that patients taking Lucemyra were more likely to remain abstinent from opioids for longer periods of time than those taking a placebo.11 This is an important benefit of Lucemyra, as it can help patients stay in recovery and avoid relapse.
Lucemyra is a revolutionary medication that has had a significant impact on the treatment of opioid withdrawal symptoms. It is effective in reducing the severity of symptoms and has fewer side effects than other medications used to treat opioid withdrawal. In addition, it has been shown to be effective in helping patients maintain abstinence from opioids. For these reasons, Lucemyra is an important tool in treating opioid addiction and helping patients stay in recovery.
1.
Promising for Monitoring and Diagnosis of AD is the finger-prick test.
2.
Multidrug Regimen Could Change Treatment Landscape for Relapsed/Refractory DLBCL
3.
Biocomputer From Human Neurons Plays Doom, Raises Ethics
4.
Artificial intelligence is assisting in the earlier detection and treatment of breast cancer.
5.
Genetics and Genetic Testing to Inform Myelofibrosis Clinical Management.
1.
A Breakthrough in Multiple Myeloma: Darzalex Delays Disease Progression by 51%
2.
The Role of Alanine Aminotransferase in Liver Health and Disease
3.
Vaso Occlusive Crisis: Understanding the Painful Reality of Sickle Cell Disease
4.
Innovative Bioengineering Approaches for Erectile Function Recovery After Radical Prostatectomy
5.
Unlocking the Power of Hematocrit: Exploring the Benefits of Blood Cell Counts
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Complexities of Ph Negative ALL - Part III
2.
From Relapse to Remission : Chasing the Invisible and Redefining Long-Term Survival in Adult R/R B-Cell ALL
3.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion
4.
Navigating the Complexities of Ph Negative ALL - Part XI
5.
Navigating the Brain Barrier: The CNS Challenge in ALK+ NSCLC
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation